IP Library Granted Patent US 8,299,052
Granted Patent B2
US 8,299,052 · App. 11/800,574 · Granted Oct 30, 2012

Pharmaceutical compositions and methods for improved bacterial eradication

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,299,052
App. No.
11/800,574
Granted
Oct 30, 2012
Kind
B2
Abstract

A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.

Claims (10)

1. A process for treating a patient for at least one of pharyngitis or tonsillitis, caused by, or suspected to be caused by, an infection of said patient by Streptococcus pyogenes, said process for treating comprising: orally administering to said patient 775 mg of amoxicillin once a day, for ten days; wherein said amoxicillin is administered in a pharmaceutical product comprising an immediate release dosage form, a first delayed release dosage form and a second delayed release dosage form, wherein said first delayed release dosage form initiates release of amoxicillin after said immediate release dosage form initiates release of amoxicillin, and wherein said second delayed release dosage form initiates release of amoxicillin after said first delayed release dosage form initiates release of amoxicillin, whereby a Total T>MIC sufficient to achieve at least an 85% bacterial eradication rate is achieved in the patient.

2. The process of claim 1 , wherein said pharmaceutical product is in tablet form.

3. The process of claim 1 , wherein said pharmaceutical product is in the form of a plurality of tablets.

4. The process of claim 1 , wherein said pharmaceutical product is in tablet form wherein, said immediate release dosage form comprises 45% of the tablet, wherein said first delayed release dosage form comprises 30% of the tablet, and wherein said second delayed release dosage form comprises 25% of the tablet.

5. The process of claim 1 , wherein said pharmaceutical product is in capsule form.

6. The process of claim 1 , wherein said pharmaceutical product is in the form of a plurality of capsules.

7. The process of claim 1 , wherein said pharmaceutical product is in the form of pellets or particles suspended in a liquid.

8. The process of claim 1 , wherein said pharmaceutical product is in the form of a sachet.

9. The process of claim 1 , wherein said pharmaceutical product is in the form of a sprinkle.

10. The process of claim 1 , wherein the Total T>MIC sufficient to achieve at least a 90% bacterial eradication rate is achieved in the patient.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2011
From: VICTORY PHARMA, INC.
To: SHIONOGI INC.
Reel/Frame 027004/0189 →
SECURITY AGREEMENT Recorded Jul 29, 2011
From: BANK OF AMERICA, N.A.
To: VICTORY PHARMA, INC.
Reel/Frame 026676/0070 →
SECURITY INTEREST Recorded Oct 8, 2010
From: VICTORY PHARMA, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 025114/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2010
From: MIDDLEBROOK PHARMACEUTICALS, INC.
To: VICTORY PHARMA, INC.
Reel/Frame 024964/0036 →
CHANGE OF NAME Recorded Nov 9, 2007
From: ADVANCIS PHARMACEUTICAL CORPORATION
To: MIDDLEBROOK PHARMACEUTICALS, INC.
Reel/Frame 020089/0910 →